ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novartis Inks Four-Year Proteome Resear
ScripMetaVia released new data on 22 April from a Phase I trial of its dual oxyntomodulin analog agonist DA-1726 that it claims might position the drug with a best-in-class safety/tolerability and efficacy
Pink SheetOn top of the recent major tariff announcement from US President Donald Trump, a ruling by South Korea’s Constitutional Court last week to go ahead with the removal of impeached former president Yoo
ScripOn top of the recent major tariff announcement from US President Donald Trump, a ruling by South Korea’s Constitutional Court last week to go ahead with the removal of impeached former president Yoo